What top brokers are saying about the Nufarm share price

The Nufarm Limited (ASX: NUF) share price has gone from being the worst performer on the S&P/ASX 200 (Index:^AXJO) (ASX:XJO) index to the best. Should you buy or sell the stock?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

From trash to treasure is probably a good way to describe the Nufarm Limited (ASX: NUF) share price over the past two days.

Nufarm is the best performing stock on the S&P/ASX 200 (Index:^AXJO) (ASX:XJO) index today with its 6.2% bounce to $4.49 followed by the Speedcast International Ltd (ASX: SDA) share price and Ardent Leisure Ltd (ASX: ALG) share price in second and third place, respectively.

Sentiment in Nufarm stands in sharp contrast to yesterday. The NUF share price tumbled to the bottom of the ASX 200 leader board on Wednesday when it suffered a more than 20% crash on the back of its profit warning and suspension of its interim dividend.

a woman

Should you sell Nufarm?

But top brokers aren't giving up on the embattled crop protection and seed products group as they continue to think that Nufarm is oversold even as management cut its FY19 earnings before interest, tax, depreciation and amortisation (EBITDA) to between $440 million and $470 million (from $500m-530m).

Worries that Nufarm will need to do an emergency capital raise and news of a second trial against its peer Bayer on the use of glyphosate (the active ingredient in Bayer's and Nufarm's weed killing products) also didn't help.

But Citigroup isn't worried about the health of its balance sheet and has reiterated its "buy" call on the stock even as it cut its price target by a buck to $6.20 a share.

Brokers sticking with their "buy" calls

"Management confirmed that banking covenants are structured to accommodate seasonal swings in the business. Furthermore, NUF has accelerated supply transition arrangements for its EU-acquired assets, initiated performance improvement program in Australia, and will focus on driving a significant reversal of the sharp 1H19 working capital build, largely from receivable collections (NAM, LATAM) and inventory sell-through," said the broker.

"Non-core asset sales and dividend suspension could provide further proceeds of $30-50m, by our estimates."

Deutsche Bank has also kept its "buy" recommendation on the stock as it lowered its valuation by 5% to $5.70 a share, but the broker acknowledged that the risk of a capital raising has grown.

"The downgrade to full year earnings and cashflow guidance was greater than anticipated, which has heightened the balance sheet risks yet again," said Deutsche.

"While the reduction in Australian ($30m) and European ($30m) earnings appears to be seasonal and transitory, earnings and cashflow guidance is predicated on normal seasonal conditions, which may not eventuate."

Meanwhile, Morgan Stanley thinks the stock is oversold and pointed out that Nufarm is trading at a 29% to other industrial stocks (excluding financials).

"This discount widens to 50-55% in FY20e/FY21e, materially worse than NUF's five-yeat average discount of ~20-25%," said the broker, which kept its "overweight" recommendation on the stock with a price target of $7.10 a share.

Credit Suisse is another that thinks the sell-off in Nufarm is an opportunity to buy the stock.

"We believe that there is a value opportunity on the basis that the market significantly over-weighting weather-driven fluctuations in earnings," explained Credit Suisse.

"There is ~A$40mn of weather related impacts in our Australian forecast. Even with some risk adjustment to that figure and A$30mn of transitional sourcing impacts in Europe, would suggest underlying EBITDA of above A$500mn."

The broker has a target price of $8.90 on Nufarm.

Motley Fool contributor Brendon Lau owns shares of Nufarm Limited. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Share Gainers

Why Kingsgate, Neuren, Newcrest, and Pushpay shares are rising today

These ASX shares are avoiding the market selloff on Tuesday.

Read more »

A young woman wearing overalls and a yellow t-shirt kicks one leg in the air showing excitement over the latest ASX 200 shares to hit 52-week highs
Share Gainers

Why Neuren, Northern Star, Race Oncology, and Westgold shares are storming higher

These ASX shares are starting the week in a positive fashion.

Read more »

A woman wearing yellow smiles and drinks coffee while on laptop.
Share Gainers

Why APM, Macquarie Telecom, Northern Star, and Origin shares are rising today

These ASX shares are having a strong session despite the market selloff.

Read more »

Two boys with cardboard rockets strapped to their backs, indicating two ASX companies with rocketing share prices
Share Gainers

Catch these fast-rising 2 ASX shares before it's too late: Celeste

This pair of stocks rocketed up in February during reporting season, but are still great value for those willing to…

Read more »

three businessmen high five each other outside an office building with graphic images of graphs and metrics superimposed on the shot.
Share Gainers

Why Arafura, Myer, Volpara, and Xero shares are zooming higher

These ASX shares are making their shareholders smile on Thursday.

Read more »

medical asx share price represented by doctor giving thumbs up
Healthcare Shares

Guess which ASX biotech stock just rocketed 29% on big FDA news

The ASX healthcare share is attracting investor interest following FDA approval for its targeted cancer therapy compound.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Share Gainers

Why Mesoblast, PolyNovo, Pushpay, and Weebit Nano shares are charging higher

These ASX shares are having a strong session despite the market selloff.

Read more »

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Share Gainers

Why InvoCare, Pentanet, Sayona Mining, and Weebit Nano shares are storming higher

These ASX shares are having a strong session on Tuesday.

Read more »